Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Intellicell Business Model
Presently, IntelliCell processes its SVFC's in a cGTP compliant cellular lab with
strict standard operation procedures (SOP's). The initial IntelliCell cellular lab is
located in its ambulatory surgical center at 460 Park Avenue, New York, NY;
doctors wishing to use cellular therapy to treat their patients may use the
IntelliCell Cellular facilities, equipment and processes. IntelliCell either supplies
its cellular products to doctors working for its affiliate Regen Medical PC for the
treatment of their patients or sells the processed SVFC's to outside physicians
who treat their patients in the IntelliCell Cellular facility. Since the SVFC's are
returned to a patient’s own body in a same-day outpatient procedure, with little or
no risk of disease transfer, rejection, or allergic reaction, IntelliCell believes it can
operate under a FDA exempt CFR 1271.15 (b) or PHS 361 CFR 1271.10 (a).
The company's expansion plan is to acquire cash flow positive ambulatory
surgery centers in major US markets beginning in 2013 with a target of operating
20 centers by 2016. Each center will generate between $10M to $30M of
revenue per annum in traditional surgical procedures such as orthopedics,
aesthetic plastic surgery, urology, etc.
IntelliCell will place a cGTP compliant cellular processing laboratory in each
surgical facility and offer regenerative medical procedures in addition to the
surgical procedures. The company believes an additional $10M to $15M can be
generated per annum from the cellular therapies at an average gross profit of
70% from the cellular procedures.
The financial model target is to reach over $600m in combined revenues by
2018. By combining surgical revenues with cell therapy revenues, the company
believes it has developed a risk mitigated market entry model and a business
model poised for sustainable growth.
Beyond the operation of providing a fully equipped and staffed surgical center for
the collection and use of SVFC's with patients, IntelliCell believes there are
additional methods the IntelliCell business model can generate value:
• Licensing its technology for international partners and additional areas of
clinical development. This could include wound care, cardiac, gastrointestinal
(colitis/ileitis), multiple sclerosis and autism to other companies in the
regenerative medicine field.
• Establishment of an SVF cellular tissue bank. IntelliCell will market this
service to liposuction patients in addition to any patient who might want to
store their SVFC's for future use3
• Fees from training and certifying physicians in the use of the IntelliCell
process
FDA
The company has been engaged in discussions with the FDA regarding
operational compliance issues and its exemption status position. FDA issued
IntelliCell a “Warning Letter” March 13, 2011, based upon a site audit of its
previous beta laboratory. The cGTP issues were resolved upon the completion of
IntelliCell's new flagship location and opening its cGTP cellular lab. Biologics
Consulting Group performed an independent quality audit of the new facility
The company and its legal and biologic advisors are currently involved with FDA
in discussions related to the company's position that it qualifies as an exempt
product from regulation as a drug. The primary reasons behind the company's
claim is that the non-structural lipoaspirate is minimally manipulated, no enzyme
or chemical is added to the cell population, the cells are not expanded or grown
in culture, and the relevant biological characteristics of the cells have not been
altered.
Discussions are expected to continue throughout 2013 and the company is
hopeful that FDA will agree with its position as an exempt product based on the
IntelliSonics™ process. Regardless of the final outcome, the company is
prepared to comply fully with any and all regulations.
Clinical Studies
To increase the value of its business model, IntelliCell is in the process of
selectively making investments to launch clinical trials so that in the future it can
make clinical claims for its cellular product. These clinical studies will be IND/IRB
FDA studies to achieve FDA approval for clinical claims. Areas under
consideration include
• Treating osteoarthritis of the knee
• Gingival gum regeneration, both of which have demonstrated safety and
efficacy in published early pre-clinical work
• Wound healing to treat non-healing diabetic ulcers
• Future product candidates include:
o Multiple sclerosis
o Erectile dysfunction
o General dermal regeneration
One of the major advantages of conducting these clinical studies is that since the
SVFC's are already used by Regen Medical PC to treat patients, the outcome of 4
the effectiveness of the treatment is already known. This is a significant
difference over traditional pharmaceutical trials where the outcome of the clinical
trial is usually not well known.
Competition
There are other companies using lipoaspirate tissue to manufacture stromal
vascular fraction. Companies, such as Cytori and Celltex, use an enzyme
(collagenese) to separate the SVFC's from the blood vessels in the adipose
tissue and they are being regulated by FDA as a drug, due to the fact that the
use of enzymes causes significant biologic manipulation.
Cytori, Celltex, Tissuegenesis, and others are utilizing a point of care device to
produce the cellular product. When factoring in the cost of the capital equipment
(as much as $70,000 each) and high disposal cost per case (as much as
$1,500), IntelliCell believes it has a superior laboratory system and process in
place.
Further, the point of care systems do not produce industry standard batch
manufacturing records demonstrating compliance with Quality Assurance that is
standard practice in any cGTP or cGMP facility. Specific cell counts, cell viability,
gram staining, endotoxin testing (all part of IntelliCell SOP's) are not included
with the point of care systems.
The Future
Once the FDA agrees with IntelliCell that it falls under either CFR 1271.15(b) or
PHS 361: CFR 1271.10 (a), the business model can be supplemented with
placing the IntelliCell Labs into other surgical centers and/or hospitals. This
would be a modified franchise model where IntelliCell would operate the labs.
The revenue stream would flow from IntelliCell licensing and/or selling the
“IntelliCell” process to the hospital or doctors for use with their patients.
CJ, I hear ya! Been accumulating and set all of my shares to $2.00 for now. Looking forward to News!
GLTA
I am sure he bought low and sold high, lol
WOW, I had to travel today, it is nice coming back to see green. Looks like a great consolidation day and nice accumulation. See some flippers left which is good for the next leg up.
SVFC$$ GLTA
Here is another treatment center in Florida
Medical Director Dr. Harold Bafitis and IntelliCell BioSciences
of Palm Beach, a division of IntelliCell BioSciences Inc.
http://www.bafitis.com/pdf/2011_stemcell_therapy.pdf
No problem, I love this Company. I hope we all make money!
In my spare time I will keep digging hoping to find that diamond in the rough article or DD.
Enjoy you're Sunday all! Spend time with the family knowing that Monday will be prosperous.
GLTA
Anyone want to go to the 2014 Stem Cell conference?
Robert J. Sexauer, Executive Vice President Clinical Development will be speaking on behalf of Intellicell Biosciences.
http://www.triconference.com/cell-therapy
3:20 Designing In-Human Clinical Studies for Cellular Therapy Applications
Robert J. Sexauer, Executive Vice President, Intellicell Biosciences
The talk will focus on the need to harmonize all of the stakeholder groups involved in clinical studies and what type of issues and challenges to expect. I will discuss clinical studies that have been completed and newer trials in development.
Mr. Sexauer has been in the medical technology industry since 1979 and has served in a series of executive corporate positions with a specialization in international clinical, corporate and product development. In 2006, he formed InterMark Associates Ltd., a London based consulting organization focused on the regenerative medicine industry. Among projects undertaken included a turn around as CEO of a California based nanotechnology company that resulted in a settlement with the SEC and redirection of the company's business. Also, Mr. Sexauer directed the first ever in human clinical trial utilizing two autologous cell lines for regenerative medicine. Prior to InterMark, he was responsible for the corporate launch of Isolagen Europe, Ltd. Isolagen developed a pioneering regenerative medicine autologous cellular application for the anti-aging and dermal regeneration market.
Mr. Sexauer has worked extensively outside the United States while also directing mergers and acquisitions at the corporate level and has been a featured guest lecturer at DePaul University in the graduate school of International Marketing. He has also been a featured speaker at national conferences in the medical and information technology sectors addressing market conditions and valuations for mergers and acquisitions.
Robert J. Sexauer, EVP of Clinical Development, stated, "Much as organ donation has saved many, many lives, this process can lead to the development of new lifesaving treatments."
IntelliCell recognizes that SVF therapies are an important part in the future of Regeneration Medicine.
According to BioInformant Worldwide LLC, "There is conclusive evidence that entering the stem cell research products market is fiscally worthwhile. Full-year 2011 analysis determines the size the stem cell research products market to be $2.59 billion, and the stem cell therapies market to be $3.13 billion, for a total of $5.72 billion. In addition, both markets are growing with double-digit growth. Producing stem cell research products thus represents a massive profit opportunity for research supply companies."
Myron Holubiak, Director, Chair of the Nominating and Governance Committee for Intellicell. Past President of Roche Labs. Do you think we have some awesome players with SVFC?
Look a little deeper in is past experiences:
Mr. Holubiak is also Chairman of the Board of Directors of BioScrip
He co-founded and served as CEO to Emron, Inc (Not to be mixed up with Enron)
Mr. Holubiak also currently serves on the Board of Trustees for the Academy of Managed Care Foundation
Mr. Holubiak is the former President of Roche Laboratories, Inc
Mr. Holubiak was President, Chief Operating Officer and member of the Board of Directors of iPhysicianNet, Inc.
Mr. Holubiak was President and Chief Operating Officer of HealthSTAR Communications, Inc.,
Mr. Holubiak is the President and a member of the board of directors of 1-800-Doctors, Inc.
Mr. Holubiak served on the board of directors of Nastech Pharmaceuticals Company, Inc. (now Marina Biotech, Inc.)
Mr. Holubiak is also a member of the board of directors of Venture Biosciences, Inc.
Yeah, when I read that I seen $ signs. They can value sell and charge a good price especially for the cosmetic side of it. There is big money in cosmetic surgery etc... Looking better and better!
Good Luck
Intellicell's partner in Canada.
The RegenaStem Cellular Treatment Centers will utilize the patent pending IntelliCell Inc. proprietary
procedures to harvest and deliver to patients Autologous Homologous SVF to treat degenerative joint
disease of the upper and lower limb with a focus on the hip, shoulder and knee.
There is a nice case study in there as well about Regeneration of human bones in hip osteonecrosis
and human cartilage in knee osteoarthritis with
autologous adipose-tissue-derived stem cells (SVFC):
a case series
http://www.regenastem.com/documents/RegenaStem_Health_Canada_Compliance_Proposal_Oct24.pdf
We were also guests for the ISSUU Stem Cell Summit in Houston:
Page 65 is our write-up.
This summit was about analysis and market forecasts for 2012-2022
http://issuu.com/rrypublications/docs/scs12_executive_summary?e=3996674/3784571
Nadendla,
The more I read about this Company I am absolutely astounded how undervalued it is! I cannot wait for upcoming months!
Here is the link to an Executive Summary:
http://proactivecapital.com/wp-content/uploads/2013/02/imtellicellfactsheet.pdf
The Future
Once the FDA agrees with IntelliCell that it falls under either CFR 1271.15(b) or
PHS 361: CFR 1271.10 (a), the business model can be supplemented with
placing the IntelliCell Labs into other surgical centers and/or hospitals. This
would be a modified franchise model where IntelliCell would operate the labs.
The revenue stream would flow from IntelliCell licensing and/or selling the
“IntelliCell” process to the hospital or doctors for use with their patients.
About SVFC's competition:
There are other companies using lipoaspirate tissue to manufacture stromal
vascular fraction. Companies, such as Cytori and Celltex, use an enzyme
(collagenese) to separate the SVFC's from the blood vessels in the adipose
tissue and they are being regulated by FDA as a drug, due to the fact that the
use of enzymes causes significant biologic manipulation.
Cytori, Celltex, Tissuegenesis, and others are utilizing a point of care device to
produce the cellular product. When factoring in the cost of the capital equipment
(as much as $70,000 each) and high disposal cost per case (as much as
$1,500), IntelliCell believes it has a superior laboratory system and process in
place.
Further, the point of care systems do not produce industry standard batch
manufacturing records demonstrating compliance with Quality Assurance that is
standard practice in any cGTP or cGMP facility. Specific cell counts, cell viability,
gram staining, endotoxin testing (all part of IntelliCell SOP's) are not included
with the point of care systems.
Clinical Studies
To increase the value of its business model, IntelliCell is in the process of
selectively making investments to launch clinical trials so that in the future it can
make clinical claims for its cellular product. These clinical studies will be IND/IRB
FDA studies to achieve FDA approval for clinical claims. Areas under
consideration include
• Treating osteoarthritis of the knee
• Gingival gum regeneration, both of which have demonstrated safety and
efficacy in published early pre-clinical work
• Wound healing to treat non-healing diabetic ulcers
• Future product candidates include:
o Multiple sclerosis
o Erectile dysfunction
o General dermal regeneration
One of the major advantages of conducting these clinical studies is that since the
SVFC's are already used by Regen Medical PC to treat patients, the outcome of 4
the effectiveness of the treatment is already known. This is a significant
difference over traditional pharmaceutical trials where the outcome of the clinical
trial is usually not well known.
This may be a good long term investment!
The company's (SVFC) expansion plan is to acquire cash flow positive ambulatory
surgery centers in major US markets beginning in 2013 with a target of operating
20 centers by 2016. Each center will generate between $10M to $30M of
revenue per annum in traditional surgical procedures such as orthopedics,
aesthetic plastic surgery, urology, etc.
IntelliCell will place a cGTP compliant cellular processing laboratory in each
surgical facility and offer regenerative medical procedures in addition to the
surgical procedures. The company believes an additional $10M to $15M can be
generated per annum from the cellular therapies at an average gross profit of
70% from the cellular procedures.
The financial model target is to reach over $600m in combined revenues by
2018. By combining surgical revenues with cell therapy revenues, the company
believes it has developed a risk mitigated market entry model and a business
model poised for sustainable growth.
Beyond the operation of providing a fully equipped and staffed surgical center for
the collection and use of SVFC's with patients, IntelliCell believes there are
additional methods the IntelliCell business model can generate value:
• Licensing its technology for international partners and additional areas of
clinical development. This could include wound care, cardiac, gastrointestinal
(colitis/ileitis), multiple sclerosis and autism to other companies in the
regenerative medicine field.
• Establishment of an SVF cellular tissue bank. IntelliCell will market this
service to liposuction patients in addition to any patient who might want to
store their SVFC's for future use3
• Fees from training and certifying physicians in the use of the IntelliCell
process
Waiting on this clinical trial to start. Patents, Clinicals,Licensing, Royalties... GO SVFC.
IntelliCell BioSciences has completed the preclinical protocols in anticipation of beginning a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013. The company provides product today to ReGen Medical, and in doing so is building fantastic database of patient experience that will be used to focus on clinical applications.
I can see a day when stem cells from these procedures are cryopreserved. Down the road, should you break your arm or your ankle, those cells could be used to help you heal rapidly. I think Cytori's device has enormous potential. I respect the fact that it is targeting CMI with a peak oxygen consumption endpoint along a PMA (device) pathway.
Once the company completes the current phase 2 study successfully, all it will need to do is one modestly sized phase 3 trial. Proving safety is less of an issue with the device pathway, so the pivotal trial's focus is a p-value (statistically valid result) on a relevant endpoint.
No big deal, we all do it and that's why we have Board family! You will be rich soon enough : )
Good job all longs! Just got back from work to see the awesome day here! That's just the beginning
Now that is funny!
It is all to do with the ultrasonic Cavitation system. They or their licensed centers can extract the cells from the fat in your body while you are waiting and not taking multiple trips. See below. When they start to license this out at 1,000,000 per license it will add up quick. They will also recieve royalties as well. Plus this technology can be used in Orthopedics, Dental,Osteoarthritis and many more. Check out the DD at top of board
NEW YORK, June 13, 2013 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm
I am thinking the Sports side of this Technology is huge in itself.
GLTY
IntelliCell Demonstrates at the American Sports Medicine Institute Held in Conjunction with and at the Andrews Sports …
NEW YORK–(BUSINESS WIRE)–
IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK) (PINKSHEETS: SVFC.PK); (“IntelliCell”) or the (“Company”), was invited to demonstrate its stromal vascular fraction technology at the recent Baseball Injuries Symposium at the Andrews Sports Medicine Institute in Alabama held and sponsored by USA Baseball. The course Chairman is Dr. James Andrews, and moderated by PT Kevin Wilk, and Dr. Jeff Dugas. One of the courses presented during the three day event was on stem cell technology presented by Dr. Joshua Hackel. Dr. Hackel presented the state of regenerative medicine technology in the role of treating sports injuries. The link is http://www.mediafire.com/?u7bfa662e3r1sdp.
Dr. Hackel compared the IntelliCell SVF technology to several other methods of regenerative medicine being considered to be used by the leading orthopedic sports medicine doctors. Dr. Steven Victor, CEO of IntelliCell stated, “We are extremely excited that IntelliCell’s technology compares very favorably to all the other technologies, for procedures common to all major sports industries. We are extremely grateful to have the opportunity to present to over 200 leading doctors and trainers looking to treat major league, collegiate and amateur baseball players with regenerative medicine. IntelliCell Biosciences believes that its technology will be utilized by such experts this year.”
Dr. James Andrews (Medical Board of Advisers SVFC)
Please just listen to the athletes he has worked on and fixed. Near the end of this video they mention the future is stem cells (SVF's)
Guess who's Technology he will be using?
Really good to see the CEO discussing the promise of this sleeping giant SVFC.
This explains some of Intellicell's Business overview:
It amuses me that there is an argument (Diversion Attempt) over 27 million versus 150 million shares. If by chance it were 150 million it is still 1.850 Billion less than most Bio stocks. SVFC is a low float mega play with Patents and Licensing opportunities!Not to mention the All Star Board and Advisers. strap on you're belts it will be a wild ride!
Everyone please know what you own and do not be fooled over thought out diversion attempts.
I sure hope not! SVFC baby!
Can't wait for the Fireworks! The longs will prosper on some Med Greens!
Did you try CPR? LOL
Welcome Xoloryro!
Gone to be a great ride!
Love the action and all the DD. In my eyes all of this is relavent as it still pertains to SVFC
No bigger news than this IMO
IntelliCell's stem cell technology validated by Merck study
by Deborah Sterescu
IntelliCell BioSciences (OTCQB:SVFC) said Thursday that its technology used to generate fat, or adipose, stem cells was tested by a division of healthcare giant Merck, with positive results.
Fat stem cells are now the cutting edge, with many doctors and companies researching the use of them for the treatment of arthritis, as well as a host of orthpedic injuries, and congestive heart failure, gum recession, wound healing, along with a several other ailments.
IntelliCell has developed an in-house technology where it can process stromal vascular fraction (SVF) cells containing a high concentration of adipose stem cells. The company believes that it is currently the only one that does not use enzymes in processing adipose tissue, and actually counts and checks the adipose stem cells they manufacture.
The company's technique takes approximately 30 minutes, and the stem cells can be returned to the doctor in the same day.
Millipore, owned by Merck, performed an antibody flow cytometry study of IntelliCell's technology, which showed that the company's manufactured cells yielded an average of 10 times the number of SVF cells containing adult adipose stem cells, from less fat than that which the IntelliCell believes is used by an of its competition using enzymes in their process.
The study also showed that IntelliCell's cells contain all of the viable cells that are manufactured by competing technologies.
"We believe IntelliCell is setting the gold standard for adipose stem cell processing without the use of enzymes and yielding high number of SVFs with adult adipose stem cell counts," said IntelliCell chairman and CEO, Dr. Steven Victor.
"We feel that our technology is a true game changer in the field of regenerative medicine and that SVF could show incredible promise for a wide range of clinical uses in the near future.
"We believe that the body stores all of the reparative and regenerative cells it could possibly need as a result of trauma or illness in the stromal vascular fraction (SVF) contained in the fat."
Indeed, these fat stem cells have similar potential to embryonic stem cells in their pluripotency, in vast number, from a source that involves no moral or ethical issues, as well as no chemical additives required for digestion of the tissue.
In the aesthetic world, the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the US FDA published its laws on autologous stem cells in mid-2009, the field has expanded rapidly.
IntelliCell has established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach.
IntelliCell's SVF stem cell technology used for basketball star, featured in NYDaily News
pm by Deborah Sterescu
IntelliCell BioScience (OTCQB:SVFC.PK) said Tuesday that its stromal vascular fraction (SVF) stem cell therapy was featured in an article in the New York Daily News over the weekend.
The company, through its proprietary technology, processes stromal vascular fraction (SVF) stem cells, derived from one's own body fat.
Fat stem cells are now the cutting edge, with many doctors and companies researching the use of them for anti-aging effects, as well as for the treatment of more serious conditions like arthritis, congestive heart failure, gum recession, and wound healing.
IntelliCell's SVF cells can be used to treat certain conditions, or rejuvinate damaged tissue and cell function. The company, which under the FDA is authorized to commercially sell its SVF cells, has also applied for a patent on its use of ultrasonic cavitations to break up fat cells, which increases the number of SVF stem cells that can be extracted from just two ounces of fat to between 500 million and 1.4 billion.
A full page Daily News article, titled “Stem Sells” written by Sean Brennan published February 19, 2012, http://www.nydailynews.com/sports/college/manhattan-basketball-torgrim-sommerfeldt-turned-stem-cell-treatment-back-court-article-1.1025227, describes how Torgrim Sommerfeldt’s budding basketball career was saved through Dr. Anthony Maddalo’s treatment using IntelliCell's proprietary SVF cell therapy.
Sommerfeldt, a former star player for the Norwegian National Basketball Team, had undergone six knee surgeries, and had forfeited his Wake Forest basketball scholarship.
However, Manhattan College took a chance on him and invited him to join their team.
In the article, Maddalo, Manhattan’s team doctor who is also the Rangers’ assistant team physician, was cited as saying: "He [Sommerfeldt] had exhausted almost every other conservative method we could possibly think of.
"He was bothered by chronic patellar tendinitis in both knees, and he had never really recovered from those operations (in Norway). He was in pain constantly. He couldn’t walk around campus without pain. We tried physical therapy, ultrasound, types of electric stimulation, exercise and stretching but nothing worked."
With limited options other than more surgery, Sommerfeldt and Maddalo decided to contact Dr. Steven Victor from Lenox Hill Hospital, who is also CEO of IntelliCell in New York City.
Due to the two IntelliCell SVF treatments in New York City by Dr. Maddalo near the end of 2010 and the beginning of 2011, Sommerfeldt started his first game for Manhattan College on January 20, 2012, "pain free", IntelliCell said.
CEO of IntelliCell BioSciences Victor, commented: "We are very proud that our proprietary technology used by Dr. Maddalo was able to rehabilitate Torgims’s knees and alleviate his pain.
"Sports related injuries are a predominate focus for our Company. Doctors using our proprietary technology have treated several professional and college athletes with excellent results. Patients have seen cartilage regrow in the knee.
"We are about to start a multi-center study for several sports injury indications at major centers. We are fortunate to have several top orthopedic surgeons on our advisory board such as; Dr. Andrews, Dr. Hackel, Dr. Dugas and Dr. Nicola.
"We believe the 2012–2013 years will see significant revenues from the use of our technology to treat athletes. We believe that this is a $1.3 billion market opportunity just in the United States."
CPReports.com says IntelliCell's therapy "a game changer"
by Joyanta Acharjee
CPreports.com issued a report on IntelliCell BioSciences (OTCQB:SVFC) which called the company's Stromal Vascular Fraction (SVF) celluar therapy "a game changer" in the treatment of orthopedic and sports inflammatory conditions.
IntelliCell BioSciences is a regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult fat tissue. It intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients.
In the research report, veteran Wall Street analyst Ray Dirks said Intellicell's SVF cell therapy was a thousand times more potent than the current therapy of cortisone for treating inflammation, but it also re-grows tissue, cartilage, and blood vessels.
"There is no other treatment on the market that has ever shown re-growth of tissue," Dirks said in his note.
Intellicell's therapy requires the taking of two ounces of fat tissue which is then broken down using ultrasonic cavitation, leaving only anti-inflammatory cells which are then re-injected back into the patient.
"The Intellicell procedure is much less invasive, much less painful, and it re-grows the damaged tissue and cartilage," Dirks said in his report.
The process is already being commercially used by doctors and is not considered a drug by the FDA so multi-year phase trials are not necessary.
Intellicell is planning a seven-center clinical study of approximately 300 patients under the direction of advisory board member Dr. James Andrews, who is the father, according to the report, of "Tommy John" surgery - a medical procedure that replaces a ligament in the elbow with a tendon from elsewhere, a common procedure among professional athletes.
A full page Daily News article, titled “Stem Sells” written by Sean Brennan published February 19, 2012, http://www.nydailynews.com/sports/college/manhattan-basketball-torgrim-sommerfeldt-turned-stem-cell-treatment-back-court-article-1.1025227, describes how Torgrim Sommerfeldt’s basketball career was saved through IntelliCell's proprietary SVF cell therapy.
There are several major baseball and American football teams that are in negotiations to purchase Intellicell lab facilities, Dirks said.
The company is also scheduled to open its first Centre of Excellence on Park Avenue in New York in April 2012. Dirks reckons this facility will be extremely profitable "out of the gate" with estimates of $20 million in revenue with a $10 million profit.
Intellicell also intends to license its technology for the treatment of heart as well as wound healing worldwide, which could lead to significant up-front cash fees that would energize the stock price.
After a recent capital raising, the company has projected to have $1.5 million of cash and no debt.
Independent research firm CPReports.com provides readers and subscribers with market commentary. Content is focused on what is going on in the stock market and on Wall Street.
Won't hold us Down too much longer with all of the things SVFC is working on.
IntelliCell BioSciences, Inc. Announces Collaborative Agreement With University Of Florida On Stem Cell And Tissue Repair Research
IntelliCell BioSciences, Inc. Signs Technology Licensing Agreement With Stem Cells 21 Thailand
IntelliCell BioSciences, Inc. Announces Study Published In The Journal of Implant & Advanced Clinical dentistry
IntelliCell BioSciences, Inc. Signs Exclusive Supply And Sale Agreement With Millipore Corporation
IntelliCell BioSciences, Inc. Announces It Has Opened Adipose Tissue Processing Center In West Palm Beach, Florida
The PAWS Pet Company, Inc. Announces Exclusive License Agreement With IntelliCell BioSciences, Inc
IntelliCell BioSciences, Inc. Announces It Has Opened An Adipose Tissue Processing Center In New Orleans
IntelliCell BioSciences, Inc. To Open Tissue Processing Center In Baton
IntelliCell BioSciences, Inc. Announces Validation Of Technology By Merck Subsidiary
Did anyone know that svfc signed exclusive with PAWS?
The PAWS Pet Company, Inc. Announces Exclusive License Agreement With IntelliCell BioSciences, Inc
The PAWS Pet Company, Inc. announced that it has entered into an exclusive license agreement with IntelliCell BioSciences, Inc., IntelliCell, a regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells. As per the terms of the agreement, The PAWS Pet Company is to exclusively market and sell IntelliCell's SVF solution in the
The PAWS Pet Company and IntelliCell BioSciences to Bring Regenerative Cell Therapy to Animals
San Jose, CA August 30, 2011 - The PAWS Pet Company, Inc. (OTCQB: PAWS) (OTCPK: PAWS) or “the Company”, the innovative pet services company, today announced it has entered into an exclusive license agreement with IntelliCell BioSciences, Inc., “IntelliCell”, (OTCPK: SVFC) a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells. Per the terms of the agreement, The PAWS Pet Company is to exclusively market and sell IntelliCell’s SVF solution in the veterinary market.
According to Hoovers, the U.S. veterinary services industry has annual revenues estimated at $25 billion.
“This is an important step in the development of the Company,” said Dan Wiesel, Chairman and CEO of The PAWS Pet Company. “This exclusive world-wide license extends our service offering beyond the pet transportation marketplace, into the fast growing market for regenerative medicine for animals. Through our trusted position with both Pet Parents and Veterinarians, we will introduce a technology that we believe will improve the wellbeing of pets.”
Dr. Steven Victor, Chairman and CEO of IntelliCell added, “We are pleased to be working with The PAWS Pet Company in bringing our leading SVF solution to the treatment of animals. The benefits of SVF in providing stem cell counts and viability checks for each specimen processed, as well as enhanced quality and quantity of the stem cells produced, will now be available to pets.”
Dr. Jeff Werber, Director of Veterinary Services with The PAWS Pet Company commented, “SVF is a proven treatment for a number of conditions including osteoarthritis, tendon repair, ligament injuries and other traumatic and degenerative diseases. The higher cell count from a smaller tissue sample means that Pets have a faster road to recovery with SVF compared to legacy enzyme-based stem cell treatments.”
Yeah,Nick described this in an email to me last week. Nick has a handle on what's going on and feels confident it will be corrected. MM manipulation of this stock has been fierce and it is no secret. There are some on this board responsible and we know who they are. No worries! I believe Nick and we are close.
Dr. Harry Fisch has joined the Board of Scientific Advisors and will head up the new Urology Department at IntelliCell.
IntelliCell's Chairman and CEO, Dr. Steven Victor stated, "Our Company is very pleased to announce today that Dr. Fisch is joining our Advisory Board and will be the Director of Urology for IntelliCell. He is a pioneering surgeon and respected on the national stage for his work on microsurgical techniques. I am looking forward to working with him as we expand the potential benefits of Regenerative Medicine into the practice of urology."
Said Dr. Fisch, "I believe that the promise of Regenerative Medicine for patients suffering from a number of urological disorders including erectile dysfunction may become an important part in the practice of medicine. This is an exciting time in medicine and I am looking forward to working with cutting edge technologies like IntelliCell's and improving the clinical outcomes of my patients."
Dr. Harry Fisch is a board certified urologist at New York Presbyterian Hospital/Weill Medical College of Cornell University. He is one of the nation's leaders in the diagnosis and treatment of Men's health issues as well as sexuality and fertility problems in couples. Internationally renowned, he has pioneered microsurgical techniques for disorders associated with male infertility such as vasectomy reversal and varicocele repair. He has been named to the “Best Doctors in America" and "New York Magazine Top Doctor" the past 9 years. He regularly appears on the Dr. Oz show as a medical expert on Men's Health.
For over fifteen years, Dr. Fisch has focused his research, practice, and surgery on male infertility and reproduction. His recent article describes a new microsurgical technique for varicocelectomy. In his private practice in Manhattan, Dr. Fisch has successfully treated thousands of men with sexuality and fertility problems. Dr. Fisch's research on sperm counts and endocrine disrupters has resulted in multiple research articles and international attention. His work has been frequently cited in a variety of publications, including USA Today, The New York Times, and The Washington Post. He has appeared on television's 60 Minutes, 20/20, CNN and Today, among many others.
Just slapped the Ask for 14000 more .032
SVFC
CJ,
I sent email to Anna Rhodes and Steven Victor yesterday in regards to future up-listing to a big board again and IND question. Below is his response with my name removed:
From: Steven Victor <rhodesvictor@aol.com>
To: Anna Rhodes <arhodes@intellicellbiosciences.com>,
Date: 06/26/2013 06:28 AM
Subject: Intellicell
Thank you for taking a stake in Intellicell. We are committed to bringing all shareholders value and look to advance the company to one of the big boards as soon as we can and we are always developing new and better technology and always file patents to protect our IP and as stated in our website we are looking to doing FDA IND for different disease entities.
We have exciting news coming in the near future for all our shareholders.
Steven Victor MD
Chairman/CEO
Intellicell Biosciences Inc
460 Park Avenue 17th Floor
New York, NY 10022
212-249-3050 Regen Medical PC
Cell 917-459-8252
Svictor@intellicellbiosciences.com
www.intellicellbiosciences.com
Www.regenmedicalpc.com
Www.victordermatologyandrejuvenation.com